Published in Blood Weekly, February 9th, 2006
MTI, an endovascular medical device company focused on neurovascular disease and disorders, will continue operations as a wholly owned subsidiary of ev3.
As a result of the acquisition, MTI stockholders will receive 0.476289 of a share of ev3 common stock for each share of MTI common stock that they own. Ev3 will issue approximately 7.0 million new shares of its common stock to MTI's...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.